Mesoblast (MESO) Stock Price, News & Analysis

Company Overview

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Key Stats

• Today's Range: $9.74 to $10.30
• 50-Day Range: $6.00 to $10.81
• 52-Week Range: $1.61 to $11.05
• Volume: 205,839 shs
• Average Volume: 826,359 shs
• Market Capitalization: $1.13 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.50
• Consensus Rating: Buy

Mesoblast Stock Analysis - MarketRank™

Mesoblast scored higher than 44% of companies evaluated by MarketBeat, and ranked 718th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Mesoblast has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Mesoblast has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Mesoblast are expected to grow in the coming year, from ($0.74) to ($0.57) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mesoblast is -8.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mesoblast is -8.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mesoblast has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.82% of the outstanding shares of Mesoblast have been sold short.

Short Interest Ratio / Days to Cover

Mesoblast has a short interest ratio ("days to cover") of 5.3.

Change versus previous month

Short interest in Mesoblast has recently decreased by 7.81%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mesoblast does not currently pay a dividend.

Dividend Growth

Mesoblast does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.82% of the outstanding shares of Mesoblast have been sold short.

Short Interest Ratio / Days to Cover

Mesoblast has a short interest ratio ("days to cover") of 5.3.

Change versus previous month

Short interest in Mesoblast has recently decreased by 7.81%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.86

News Sentiment

Mesoblast has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Mesoblast this week, compared to 3 articles on an average week.

Search Interest

11 people have searched for MESO on MarketBeat in the last 30 days. This is an increase of 120% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Mesoblast to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mesoblast insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.80% of the stock of Mesoblast is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 1.43% of the stock of Mesoblast is held by institutions.

MESO Stock Analysis - Frequently Asked Questions

How have MESO shares performed this year?

Mesoblast's stock was trading at $2.20 at the beginning of the year. Since then, MESO stock has increased by 351.4% and is now trading at $9.93.
View the best growth stocks for 2024 here.

How were Mesoblast's earnings last quarter?

Mesoblast Limited (NASDAQ:MESO) released its earnings results on Wednesday, August, 30th. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.06. The company had revenue of $2.14 million for the quarter, compared to analyst estimates of $2 million.

When did Mesoblast's stock split?

Mesoblast's stock reverse split on the morning of Friday, January 5th 2024. The 1-2 reverse split was announced on Friday, January 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split.

When did Mesoblast IPO?

Mesoblast (MESO) raised $69 million in an initial public offering on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

Who are Mesoblast's major shareholders?

Mesoblast's top institutional shareholders include Creative Planning (0.02%) and Perkins Coie Trust Co (0.01%).

How do I buy shares of Mesoblast?

Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Mesoblast own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mesoblast investors own include NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Meta Platforms (META), CRISPR Therapeutics (CRSP) and Corbus Pharmaceuticals (CRBP).

Company Calendar

• Last Earnings: 8/30/2023
• Today: 10/17/2024
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MESO
• Previous Symbol: OTCMKTS:MBLTY
• CUSIP: N/A
• CIK: 1345099
• Web: www.mesoblast.com
• Phone: (139) 639-6036
• Fax: 61-3-9639-6030
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $11.50
• High Stock Price Target: $12.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +15.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 1.18
• Quick Ratio: 1.18

Sales & Book Value

• Annual Sales: $5.90 million
• Price / Sales: 192.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.21 per share
• Price / Book: 2.36

Miscellaneous

• Outstanding Shares: 114,178,000
• Free Float: 92,713,000
• Market Cap: $1.13 billion
• Optionable: Optionable
• Beta: 3.47